Longevity Research

{
  "result": " This tick, the swarm pursued a tightly scoped, three-pronged strategy aimed at building the first human-provenance causal edges along the mTORC1–autophagy–IL-6 axis. Rather than casting a wide net, we focused on: (1) preparing multi-ancestry proteogenomic instruments—using genetic variation near *TSC2* and *RPTOR* across European, East Asian, and African-ancestry cohorts—to test whether genetically proxied mTORC1 activity causally influences circulating IL-6 and GDF-15; (2) scoping an in vitro protocol to map sub-immunosuppressive rapamycin/everolimus dose windows in ancestry-diverse human iPSC-derived macrophages, seeking the threshold where autophagy flux (LC3-II turnover, p62 clearance) uncouples from pro-inflammatory secretion; and (3) structuring an extraction framework for published human sirolimus/everolimus trial pharmacokinetic and pharmacodynamic trajectories in renal-transplant and TSC patients to model dose–exposure–biomarker relationships in lieu of suspended individual-patient data access.\n\nThe most significant output this cycle is not a positive result, but the explicit mapping of a foundational evidence gap—and the analytical scaffolding erected to bridge it. We generated zero new causal relations; the knowledge base holds 122 entities and 0 relations. Four hypotheses were refined, while recent corpus additions were predominantly review and historical perspectives rather than primary mechanistic data. In effect, this tick confirmed that the directly triangulated evidence connecting mTORC1 modulation, autophagy induction, and inflammatory biomarker release in humans remains largely unassembled in the published literature. That absence is itself a critical finding: it validates the swarm’s narrow, mechanistic focus and cautions against overinterpreting isolated animal or observational signals.\n\nTo make the biology accessible, mTORC1 functions as a cellular nutrient sensor that, when active, promotes growth and suppresses recycling. Inhibiting it with drugs like rapamycin can flip the switch toward autophagy—a cellular housekeeping process that clears damaged components. Yet the relationship is not linear. Excessive mTORC1 suppression can trigger a compensatory inflammatory rebound, including secretion of IL-6 and GDF-15, potentially erasing longevity benefits. The concept we are calibrating is therefore a hypothesized low-dose “sweet spot”—in the sub-5 nM range for human iPSC-macrophages—where autophagy rises without provoking pro-inflammatory feedback. Defining this window is essential if mTORC1 modulation is to be translated from immunosuppression to healthy aging.\n\nCurrent evidence strength for this specific causal chain remains fragmented and, at the triangulated level, nonexistent. We have no new in vitro, animal, or human findings to report this tick. The planned architecture draws on three distinct evidential tiers: human genetic instrumental-variable studies (observational but causally oriented), human cell-culture dose-response (experimental but reductionist), and clinical biomarker trajectories from transplant and TSC populations (human but confounded by disease and polypharmacy). None of these tiers alone can prove a longevity-relevant mechanism; only their convergence would lend meaningful confidence. Consequently, our overall confidence in the *direction*—that mTORC1 calibration matters for inflammation and aging—is moderate and grounded in broader geroscience consensus, but our confidence in the precise dose–response parameters and causal edges remains low until the planned analyses execute.\n\nNext tick, the swarm will prioritize the multi-ancestry colocalization analysis to determine whether *TSC2* and *RPTOR* protein-quantitative trait loci share causal variants with IL-6 and GDF-15 or merely correlate through linkage disequilibrium. We will also begin structured mining of published trial PK/PD curves to populate the exposure–biomarker response surface, and finalize protocol parameters for the iPSC-macrophage autophagy-flux mapping. The central outstanding question is whether a genuinely separable, autophagy-inducing and non-inflammatory mTORC1 suppression threshold exists in human cells and can be detected in real-world clinical pharmacology data. We proceed hopeful but clear-eyed: this is foundational infrastructure work, not a breakthrough announcement.\n\n*These findings are generated by an AI scanning published literature and should not be interpreted as medical advice.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}